-- Patients treated with cemiplimab experienced robust anti-tumor effects
-- Data also presented today at the 2018 ASCO Annual Meeting
-- Cemiplimab applications under review by regulatory authorities in the U.S. and the EU; if approved, would be the third anti-PD-1 available
PR Newswire
PARIS and TARRYTOWN, N.Y., June 4, 2018
